Incyte management check

INCY · Health Care · Biotechnology · CEO William Meury

Filings as of

61
Management score, ranked 300th of 487 · 35th of 60 in Health Care2 good · 4 to watch · 0 flaggedStrongest: dilution · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Watch

    Have owners done well?

    Trailed its chosen peersOwners$114Peers$120

    What $100 became since fiscal 2021

    4349th
    Detail

    $100 invested at the start of fiscal 2021 grew to $114, against $120 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9274th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.85 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    2.5% of net income

    $32.1m pay · $1.3bn net income, FY2025

    0.1%1%3%10%
    1723rd
    Detail

    $32.1m of reported pay in fiscal 2025, against $1.3bn of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing
    ——

    Light activity: no buys, $49.2m sold in six months. 39 of 39 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 222m2025 · 201m

    Diluted shares −5.7% a year; flagged above +2%

    0%10%20%

    Stock pay 4.8% of revenue

    100100th
    Detail

    Diluted shares changed -5.7% a year over the last three fiscal years. Stock-based pay was 4.8% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    8 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Mr. Hoppenot, Mr. Meury

    4521st
    Detail

    CEOs in the pay table: Mr. Hoppenot, Mr. Meury. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Watch

    Are the books clean?

    An annual report was amended

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 110-K amended
    7015th
    Detail

    No restatements, auditor changes or late filings since 2021. 1 amended annual report.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 28, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$27.4m$54.7m$10020212022202320242025$114$120

Pay tied most to total product revenues

Other key measuresTotal product revenuesPipeline development and progressionTotal shareholder return (TSR)

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Hoppenot, Mr. Meury$32.1m$54.7m$6.3m$114$120$1.3bn
2024Mr. Hoppenot$17.5m$25.2m$5.9m$79$91$32.6m
2023Mr. Hoppenot$16.7m$7.8m$7.8m$72$92$597.6m
2022Mr. Hoppenot$16.7m$16.0m$5.8m$92$89$340.7m
2021Mr. Hoppenot$14.4m$6.2m$5.2m$84$99$948.6m

Insiders and the CEO's stakeQuiet

Chief Executive Officer
William Meury
Shares held
183,129
Latest Form 4
Jul 16, 2026

Light activity: no buys, $49.2m sold in six months. 39 of 39 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldSteven H SteinCMO & Head of Late-Stage Dev. · 10b5-1 plan$31.9mNov 16, 2026
  • SoldPablo J CagnoniPresident, Global Head of R&D · 10b5-1 plan$9.3mNov 16, 2026
  • SoldPatrick A MayesEVP & Chief Scientific Officer · 10b5-1 plan$6.0mAug 5, 2026
  • SoldLee HeesonEVP, Head of Incyte Intl · 10b5-1 plan$1.3mNov 13, 2026

Leadership and governance on file

20222023202420252026Leadership 13Red flags 1Votes 5
All 14 filings

Latest shareholder vote results: Jun 9, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $2.0bn returned to owners in buybacks and dividends, 63% of net income, and $1.1bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$1.0bn$2.0bn20212022202320242025Shares222m224m226m211m201m
Show the figures
Fiscal year20212022202320242025
Revenue$3.0bn$3.4bn$3.7bn$4.2bn$5.1bn
Net income$948.6m$340.7m$597.6m$32.6m$1.3bn
Stock-based pay$183.0m$188.4m$215.9m$266.1m$249.3m
Buybacks—$0$0$2.0bn$0
Dividends—————
Diluted shares222m224m226m211m201m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.